URGN
Price:
$11.93
Market Cap:
$502.42M
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. The ...[Read more]
Industry
Biotechnology
IPO Date
2017-05-04
Stock Exchange
NASDAQ
Ticker
URGN
According to UroGen Pharma Ltd.’s latest financial reports and current stock price. The company's current PE Ratio is -3.94. This represents a change of -15.24% compared to the average of -4.65 of the last 4 quarters.
The mean historical PE Ratio of UroGen Pharma Ltd. over the last ten years is -15.21. The current -3.94 PE Ratio has changed 2.49% with respect to the historical average. Over the past ten years (40 quarters), URGN's PE Ratio was at its highest in in the December 2016 quarter at 3.11. The PE Ratio was at its lowest in in the September 2017 quarter at -345.11.
Average
-15.21
Median
-6.94
Minimum
-86.23
Maximum
-1.85
Discovering the peaks and valleys of UroGen Pharma Ltd. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 553.74%
Maximum Annual PE Ratio = -1.85
Minimum Annual Increase = -78.23%
Minimum Annual PE Ratio = -86.23
Year | PE Ratio | Change |
---|---|---|
2023 | -4.23 | 128.27% |
2022 | -1.85 | -3.37% |
2021 | -1.92 | -37.22% |
2020 | -3.05 | -55.17% |
2019 | -6.81 | -24.00% |
2018 | -8.97 | -52.24% |
2017 | -18.77 | -78.23% |
2016 | -86.23 | 553.74% |
2015 | -13.19 | 86.86% |
2014 | -7.06 | -21.15% |
The current PE Ratio of UroGen Pharma Ltd. (URGN) is less than than its 3-year, less than than its 5-year, and greater than its 10-year historical averages
3-year avg
-2.67
5-year avg
-3.57
10-year avg
-15.21
UroGen Pharma Ltd.’s PE Ratio is less than Eliem Therapeutics, Inc. (-2.42), less than Inhibrx Biosciences, Inc. (0.14), greater than Merrimack Pharmaceuticals, Inc. (-8.92), greater than Celcuity Inc. (-7.15), greater than Enliven Therapeutics, Inc. (-16.05), less than Ikena Oncology, Inc. (-1.24), less than Xilio Therapeutics, Inc. (-1.27), less than Protara Therapeutics, Inc. (-1.35), greater than Scholar Rock Holding Corporation (-13.14), less than Vaccitech plc (-2.49), less than Generation Bio Co. (-0.91), less than Kronos Bio, Inc. (-0.56), greater than Erasca, Inc. (-3.95), greater than C4 Therapeutics, Inc. (-4.26), greater than Edgewise Therapeutics, Inc. (-27.83), less than Ovid Therapeutics Inc. (-2.81), less than Connect Biopharma Holdings Limited (8.69), less than PepGen Inc. (-2.47), greater than Tyra Biosciences, Inc. (-11.91), greater than Compass Therapeutics, Inc. (-5.11), less than Vigil Neuroscience, Inc. (-1.87), greater than PureTech Health plc (-54.81),
Company | PE Ratio | Market cap |
---|---|---|
-2.42 | $342.68M | |
0.14 | $225.10M | |
-8.92 | $223.97M | |
-7.15 | $568.78M | |
-16.05 | $1.31B | |
-1.24 | $83.00M | |
-1.27 | $63.29M | |
-1.35 | $53.43M | |
-13.14 | $2.50B | |
-2.49 | $192.73M | |
-0.91 | $144.16M | |
-0.56 | $57.28M | |
-3.95 | $810.79M | |
-4.26 | $455.30M | |
-27.83 | $3.23B | |
-2.81 | $83.75M | |
8.69 | $66.30M | |
-2.47 | $221.28M | |
-11.91 | $865.93M | |
-5.11 | $233.90M | |
-1.87 | $153.44M | |
-54.81 | $498.68M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like UroGen Pharma Ltd. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like UroGen Pharma Ltd. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is UroGen Pharma Ltd.'s PE Ratio?
How is the PE Ratio calculated for UroGen Pharma Ltd. (URGN)?
What is the highest PE Ratio for UroGen Pharma Ltd. (URGN)?
What is the 3-year average PE Ratio for UroGen Pharma Ltd. (URGN)?
What is the 5-year average PE Ratio for UroGen Pharma Ltd. (URGN)?
How does the current PE Ratio for UroGen Pharma Ltd. (URGN) compare to its historical average?